Medtronic (NYSE:MDT) Stock Rating Reaffirmed as “Buy” by TD Cowen

Medtronic (NYSE:MDT)‘s stock had its “buy” rating reissued by stock analysts at TD Cowen in a research report issued on Wednesday, MarketBeat.com reports. They presently have a $110.00 target price on the medical technology company’s stock. TD Cowen’s price target would suggest a potential upside of 27.25% from the stock’s current price.

Several other research firms have also recently commented on MDT. Jefferies Financial Group restated a “hold” rating and set a $88.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Sanford C. Bernstein cut their price objective on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Mizuho set a $115.00 price objective on Medtronic in a report on Wednesday, September 2nd. Stifel Nicolaus upped their price objective on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a report on Wednesday, September 2nd. Finally, Truist Financial reiterated a “hold” rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average price target of $103.92.

Medtronic Price Performance

Medtronic stock traded down $0.64 during midday trading on Wednesday, hitting $86.45. 26,613,890 shares of the company’s stock were exchanged, compared to its average volume of 9,184,859. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33. The stock has a 50-day moving average price of $90.00 and a two-hundred day moving average price of $84.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The company has a market cap of $110.58 billion, a P/E ratio of 21.29, a PEG ratio of 2.04 and a beta of 0.56.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts forecast that Medtronic will post 5.98 earnings per share for the current year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Institutional investors and hedge funds have recently bought and sold shares of the business. Gradient Investments LLC lifted its holdings in Medtronic by 3.9% in the 2nd quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after buying an additional 18,509 shares during the period. Czech National Bank lifted its holdings in Medtronic by 4.7% in the 2nd quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after buying an additional 16,292 shares during the period. Cerity Partners LLC lifted its holdings in Medtronic by 12.7% in the 4th quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after buying an additional 89,111 shares during the period. Verity & Verity LLC lifted its holdings in Medtronic by 5.1% in the 2nd quarter. Verity & Verity LLC now owns 229,707 shares of the medical technology company’s stock worth $17,970,000 after buying an additional 11,197 shares during the period. Finally, Panagora Asset Management Inc. lifted its holdings in Medtronic by 5.3% in the 4th quarter. Panagora Asset Management Inc. now owns 749,064 shares of the medical technology company’s stock worth $71,955,000 after buying an additional 37,518 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received U.S. FDA clearance and European CE Mark approval for its Affera Prism-2 Mapping Software, while also securing CE Mark approval for the PulseSelect ProxBox Adapter with Proximity Indicator software. The products expand cardiac mapping and real-time tissue-proximity capabilities for ablation procedures, potentially supporting adoption of Medtronic’s electrophysiology portfolio. Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
• Positive Sentiment: The company also obtained FDA 510(k) clearance for its LigaSure RAS Maryland jaw device for the Hugo robotic-assisted surgery system. The approval broadens Hugo’s energy-instrument lineup and could make the platform more attractive to hospitals evaluating robotic surgery systems. Medtronic gets FDA clearance for LigaSure RAS device
• Positive Sentiment: TD Cowen reaffirmed its “Buy” rating and set a $110 price target, indicating substantial potential upside from recent trading levels. Elevated call-option activity also suggests increased speculative interest in the shares.
• Neutral Sentiment: Analysts and value-focused coverage continue to highlight Medtronic as a long-term value stock, supported by its scale, recurring medical-device demand and dividend profile. However, these assessments are longer-term catalysts rather than immediate earnings drivers.
• Negative Sentiment: Medtronic recently underperformed the broader market, and the stock remains below its 50-day moving average. That recent weakness may be keeping investors cautious despite the regulatory wins and constructive analyst commentary.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.